LOS ANGELES-- (BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented efficacy and safety outcomes in a subgroup of patients from the NALA trial who had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results